Pages that link to "Q29617685"
The following pages link to Targeting PI3K signalling in cancer: opportunities, challenges and limitations (Q29617685):
Displaying 50 items.
- Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment (Q21245749) (← links)
- PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth (Q24292938) (← links)
- A beta version of life: p110β takes center stage (Q24293200) (← links)
- Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells (Q24303535) (← links)
- P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation (Q24305925) (← links)
- Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes (Q24306865) (← links)
- AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas (Q24336818) (← links)
- Cell signaling by receptor tyrosine kinases (Q24598357) (← links)
- Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage (Q24603171) (← links)
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy (Q24628724) (← links)
- Therapeutic Implications of Targeting AKT Signaling in Melanoma (Q24631438) (← links)
- Mast cell homeostasis and the JAK-STAT pathway (Q24632515) (← links)
- Targeting the PI3K signaling pathway in cancer (Q24647554) (← links)
- Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments (Q26750649) (← links)
- Advances in targeted and immunobased therapies for colorectal cancer in the genomic era (Q26751344) (← links)
- KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment (Q26751520) (← links)
- Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics (Q26766292) (← links)
- PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma (Q26766293) (← links)
- Olive Oil and the Hallmarks of Aging (Q26769864) (← links)
- Targeting RTK Signaling Pathways in Cancer (Q26781278) (← links)
- The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life (Q26785614) (← links)
- Autophagy in airway diseases: a new frontier in human asthma? (Q26786115) (← links)
- Progress toward overcoming hypoxia-induced resistance to solid tumor therapy (Q26796405) (← links)
- Redox Regulation in Cancer Stem Cells (Q26798198) (← links)
- Tumour Angiogenesis and Angiogenic Inhibitors: A Review (Q26798822) (← links)
- The PI3K/AKT Pathway and Renal Cell Carcinoma (Q26800216) (← links)
- New and emerging factors in tumorigenesis: an overview (Q26801253) (← links)
- The role of obesity in gastrointestinal cancer: evidence and opinion (Q26825678) (← links)
- What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway (Q26825780) (← links)
- Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. (Q26827810) (← links)
- Growth factor and signaling pathways and their relevance to prostate cancer therapeutics (Q26827975) (← links)
- Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis (Q26830671) (← links)
- The Akt-associated microRNAs (Q26830734) (← links)
- Ten things you should know about protein kinases: IUPHAR Review 14 (Q26849417) (← links)
- The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges (Q26851852) (← links)
- Emerging roles of PDGF-D in EMT progression during tumorigenesis (Q26859634) (← links)
- Emerging therapeutic biomarkers in endometrial cancer (Q26865904) (← links)
- Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches (Q26995360) (← links)
- The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer (Q26997789) (← links)
- Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications (Q27009016) (← links)
- Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine (Q27015048) (← links)
- Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma (Q27026544) (← links)
- Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling (Q27317429) (← links)
- Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases (Q27675831) (← links)
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (Q27851586) (← links)
- The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis (Q27851848) (← links)
- A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal (Q27851995) (← links)
- PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation (Q27852528) (← links)
- Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. (Q27853074) (← links)
- First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors (Q27853088) (← links)